β-blockers in diabetic patients with heart failure

JAMA Internal Medicine

Volumn 175, Issue 4, 2015, Pages 657-

  Santulli, Gaetano ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; METOPROLOL; PROPANOLAMINE DERIVATIVE;

BLOOD VESSEL TONE; DIABETES MELLITUS; GLUCOSE HOMEOSTASIS; HEART FAILURE; HUMAN; INSULIN RELEASE; LETTER; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; DRUG EFFECTS; FEMALE; HEART LEFT VENTRICLE FUNCTION; MALE; MORTALITY;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; FEMALE; HEART FAILURE; HUMANS; MALE; METOPROLOL; PROPANOLAMINES; VENTRICULAR FUNCTION, LEFT;

EID: 84928193730     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.8009     Document Type: Letter

References (5)

1. Pasternak B, Svanström H, Melbye M, Hviid A. Association of treatment with carvedilol vsmetoprolol succinate and mortality in patients with heart failure. JAMA Intern Med. 2014;174(10):1597-1604.
2. Arnold SV, Spertus JA, Lipska KJ, et al. Type of β-blocker use among patients with versus without diabetes aftermyocardial infarction. Am Heart J. 2014;168(3):273-279.e1.
3. Kveiborg B, Hermann TS, Major-Pedersen A, et al. Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study. Cardiovasc Diabetol. 2010;9:21.
4. Santulli G, Lombardi A, Sorriento D, et al. Age-related impairment in insulin release: the essential role of β(2)-adrenergic receptor. Diabetes. 2012;61(3):692-701.
5. Ciccarelli M, Cipolletta E, Santulli G, et al. Endothelial beta2 adrenergic signaling to AKT: role of Gi and SRC. Cell Signal. 2007;19(9):1949-1955.